Due to a combination of growing consumer interest and occasional supply chain issues, GLP-1 medications may be difficult to obtain
Rapid weight loss, particularly without adequate protein and resistance training, can lead to muscle loss, which becomes harder to reverse with age
Food and Drug Administration: (May 2022) Approved as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus (November 2023) Approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (December 2024) Expanded indication for moderate-to-severe obstructive sleep apnea in adults with obesity Classified as first-in-class dual GIP/GLP-1 receptor agonist Not approved for type 1 diabetes mellitus or as monotherapy in patients with history of pancreatitis International Regulatory Approvals GLP2 has received regulatory approval in multiple jurisdictions: European Union (September 2022) Type 2 diabetes treatment United Kingdom (November 2023) Expanded to include weight management Canada (November 2022) Type 2 diabetes indication Australia (December 2022) Type 2 diabetes treatment Additional regulatory reviews ongoing in other countries Warnings and Contraindications Important safety considerations include: Boxed Warning for thyroid C-cell tumor risk (based on rodent studies
For many people with diabetes, managing weight is an important aspect of controlling the disease
Look for recurring charges or new charges with slightly different amounts
To increase the therapeutic effectiveness of GLP-1 in people with type 2 diabetes mellitus (T2DM), attempts have been made to prolong its half-life in the body
